{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:25:50Z","timestamp":1793046350572,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The coronavirus disease 2019 (COVID-19) pandemic has caused a significant burden of morbidity and mortality worldwide, with solid organ transplant recipients (SOTRs) being particularly vulnerable. Nirmatrelvir and ritonavir have demonstrated the potential for reducing the risk of hospitalization and death in patients with mild-to-moderate COVID-19. However, ritonavir has a strong drug\u2013drug interaction with CYP3A-dependent drugs such as calcineurin inhibitors, potentially leading to rapid increases in blood concentration. As SOTRs are commonly prescribed immunosuppressants, co-administration with nirmatrelvir\/ritonavir requires careful consideration. To address this issue, we conducted a literature review to evaluate the use and adverse effects of nirmatrelvir\/ritonavir in SOTRs and explore feasible immunosuppressant adjustment regimens. Our findings suggest that nirmatrelvir\/ritonavir could be a feasible treatment option for COVID-19 in SOTRs, provided that appropriate immunosuppressive drug management is in place during co-administration. Although prescribing the novel anti-SARS-CoV-2 drug to transplant recipients poses challenges, potential strategies to overcome these issues are discussed. Further studies are needed to determine the optimal dosing strategies of nirmatrelvir\/ritonavir, immunosuppressant adjustment, and monitoring in this patient population.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1150341","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T10:17:39Z","timestamp":1680603459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Optimizing the use of nirmatrelvir\/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies"],"prefix":"10.3389","volume":"14","author":[{"given":"Yangming","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8169","article-title":"The emergence of SARS-CoV-2 in Europe and north America","volume":"370","author":"Worobey","year":"2020","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"B5","unstructured":"FDA(COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-192021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug\u2013drug interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B10","unstructured":""},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15967","article-title":"COVID-19 in kidney transplant recipients","volume":"20","author":"Nair","year":"2020","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16997","article-title":"Effect of nirmatrelvir\/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients","volume":"22","author":"Wang","year":"2022","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am J Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14752","article-title":"Single-center experience with nirmatrelvir\/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression","volume":"36","author":"Mecadon","year":"2022","journal-title":"Clin Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2","volume":"7","author":"Devresse","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17140","article-title":"COVID-19 therapeutics and outcomes among solid organ transplant recipients during the omicron BA.1 era","volume":"22","author":"Hedvat","year":"2022","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/jasms.2c00204","article-title":"A UPLC-MS\/MS method for plasma biological monitoring of nirmatrelvir and ritonavir in the context of SARS-CoV-2 infection and application to a case","volume":"33","author":"Guyon","year":"2022","journal-title":"J Am Soc Mass Spectrom"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01180-4","article-title":"Paxlovid-tacrolimus drug-drug interaction in a 23-Year-Old female kidney transplant patient with COVID-19","volume":"42","author":"Berar Yanay","year":"2022","journal-title":"Clin Drug Investig"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: A case report","volume":"54","author":"Prikis","year":"2022","journal-title":"Transplant Proc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac238","article-title":"Supratherapeutic tacrolimus concentrations with Nirmatrelvir\/Ritonavir in solid organ transplant recipients requiring hospitalization: A case series using rifampin for reversal","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12890\/2022_003528","article-title":"Paxlovid with caution: Novel case of paxlovid-induced tacrolimus toxicity in a cardiac transplant patient","volume":"9","author":"Shah","year":"2022","journal-title":"Eur J Case Rep Intern Med"},{"key":"B22","article-title":"Case report: Nirmatrelvir\/Ritonavir and tacrolimus in a kidney transplant recipient with COVID-19","volume":"105","author":"Lindauer","year":"2022","journal-title":"Am Fam Physician"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05712-0","article-title":"Elevated tacrolimus levels after treatment with nirmatrelvir\/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant","volume":"38","author":"Young","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2022.08.029","article-title":"Risks of paxlovid in a heart transplant recipient","author":"Stawiarski","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.01.268","article-title":"Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus","volume":"54","author":"Mertz","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for covid-19: Guidelines from the French society of pharmacology and therapeutics (SFPT)","volume":"77","author":"Lemaitre","year":"2022","journal-title":"Therapies"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003002","article-title":"Ritonavir-boosted antiretroviral therapy precipitating tacrolimus toxicity in a renal transplant patient: Is it time for a priori tacrolimus dosage reduction","volume":"35","author":"Naccarato","year":"2021","journal-title":"AIDS"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50171","article-title":"Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients","volume":"9","author":"Jain","year":"2003","journal-title":"Liver Transpl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01158-7","article-title":"Yes we can (Use Nirmatrelvir\/Ritonavir even in high immunological risk patients treated with immunosuppressive drugs)","volume":"61","author":"Lemaitre","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants","volume":"22","author":"Lange","year":"2022","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2022","journal-title":"Ther Drug Monit"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-234839","article-title":"Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis","volume":"13","author":"Sharma","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922007499","article-title":"Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers","volume":"39","author":"Hebert","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","unstructured":"Molnupiravir\n          COVID-19 treatment guidelines"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1150341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T10:17:43Z","timestamp":1680603463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1150341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2023.1150341"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1150341","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1150341"}}